Colitis

Three New Articles in the Journal of Pharmaceutical Analysis Demonstrate the Potential of Natural Compounds to Treat Gastrointestinal Disorders

Retrieved on: 
Mardi, novembre 28, 2023
Hepatitis, MEFV, Dave's Picks Volume 13, Hope, Pneumonia, Liver, HSP90, Panax notoginseng, Macrophage, Mouse, Journal, Colitis, Metabolism, Ulcerative colitis, Ethanol, GI, NLRP3, SNZ, ALD, UC, JPA, Pharmaceutical industry

XI'AN, China, Nov. 28, 2023 /PRNewswire/ -- Chronic gastrointestinal (GI) disorders are becoming increasingly common throughout the world, but many of them still lack effective treatment. Researchers have now turned to natural compounds, such as those present in traditional medicines, to search for potential drug candidates for difficult-to-treat diseases. The latest issue of the Journal of Pharmaceutical Analysis (JPA) features three articles that report promising findings and could pave the way to treatments for complex diseases affecting the liver and intestine. 

Key Points: 
  • Researchers have now turned to natural compounds, such as those present in traditional medicines, to search for potential drug candidates for difficult-to-treat diseases.
  • The latest issue of the Journal of Pharmaceutical Analysis (JPA) features three articles that report promising findings and could pave the way to treatments for complex diseases affecting the liver and intestine.
  • The article was available online in July 2023 and published in Volume 13, Issue 9 of JPA in September 2023 .
  • Moreover, Rk2 also restored intestinal barrier function by enhancing NLPR6 signaling in the intestine, demonstrating its multifaceted therapeutic potential.

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Retrieved on: 
Mercredi, novembre 15, 2023
DRD2, Annual general meeting, Therapy, Eosinophilia, Disulfiram-like drug, Lymphocyte, Patient, KZIA, PNOC, Colitis, Mucositis, MD, Trial of the century, Diagnosis, DMG, Hyperglycemia, ONC201, Physician, OS, Society, Hypokalemia, DMG interpersonal, Pharmaceutical industry

The preliminary results from a single cohort in this Pacific Pediatric Neuro-Oncology Consortium (PNOC) sponsored cooperative group clinical study will be presented on Sunday, 19 November 2023 in Vancouver, Canada.

Key Points: 
  • The preliminary results from a single cohort in this Pacific Pediatric Neuro-Oncology Consortium (PNOC) sponsored cooperative group clinical study will be presented on Sunday, 19 November 2023 in Vancouver, Canada.
  • Sixty-eight children and young adults with DMG who completed standard of care radiation treatment received paxalisib (an investigational PI3K-mTOR dual inhibitor) and ONC201 (an investigational dopamine receptor D2 (DRD2) and ClpP agonist).
  • The abstract reported that median overall survival (OS) from time of diagnosis was 16.5 months.
  • "The PNOC022 study has exceeded expectations in terms of enrolment rates and has partnered with 29 leading children's cancer centers and physicians across the globe."

Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program

Retrieved on: 
Mardi, novembre 14, 2023
Arthritis, Messenger, Quicc!, Autoimmunity, SAN, OTC, Cell, Colitis, Vaccine, NR2F6

SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of its DuraCAR CAR T-cell therapeutic ( https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-exp... ).

Key Points: 
  • SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of its DuraCAR CAR T-cell therapeutic ( https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-exp... ).
  • This program is designed to create chimeric antigen T-cells that silence the gene for NR2F6.
  • "If these cells do indeed suppress these immune cells, then we will have in hand a potentially extremely valuable approach to suppressing autoimmunity."
  • Future experiments will then be designed to optimize these cells for protecting against major autoimmune disorders such as type 1 diabetes, colitis and arthritis.

Blackbird Labs, a Next-Generation Life Sciences Accelerator, Launches with $100 Million and Foundational Collaboration with Johns Hopkins University

Retrieved on: 
Mardi, novembre 7, 2023
UMB, Colitis, DSM-IV codes, History of the University of Maryland, College Park, Innovation, Crohn's disease, Johns Hopkins University, RNA, Johns Hopkins, Biotechnology, Laboratory, University of Maryland, College Park, Research, Inflammation, RA, Lieber Institute for Brain Development, Drug development, Senior, Scripps Research, Clinical trial, Economic development, Ecosystem, Schizophrenia, Messenger, University, Senior advisor, Cancer, Entrepreneurship, Economy, Patient, Pharmaceutical industry, Management

BALTIMORE, Nov. 7, 2023 /PRNewswire/ -- Blackbird Laboratories, Inc. ("Blackbird Labs"), a next-generation life sciences accelerator, today announced that it has launched with a $100 million founding grant from The Stephen and Renee Bisciotti Foundation and research collaborations with Johns Hopkins University, the University of Maryland, Baltimore, and the Lieber Institute for Brain Development. Blackbird Labs' mission is to accelerate the development and commercialization of novel medicines and cutting-edge technologies to enhance the well-being of patients facing unmet medical needs.   

Key Points: 
  • Blackbird Labs provides capital, program management, and strategic scientific and business input from its newly recruited team of life sciences professionals, seeking to bridge the gap between pioneering academic science and industry.
  • Blackbird Labs is led by Matt Tremblay, Ph.D., the CEO and a founding member of the board of directors since Blackbird Labs' creation in January 2023.
  • Blackbird Labs launches with a world-class group of advisors spanning the global life sciences venture investment community and business leaders.
  • "Blackbird Labs is an exciting new element of our innovation ecosystem, a unique resource for funding and expertise to help bring Johns Hopkins technologies to market.

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

Retrieved on: 
Mercredi, novembre 1, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Survival, Patient, Colitis, Nephritis, Cholangiocarcinoma, Incidence, Hypothyroidism, Pneumonitis, NYSE, Food, Progression-free survival, Fatigue, Medicine, Itch, DOR, AST, Pembrolizumab, Cisplatin, Head, Gastrointestinal cancer, MRK, PFS, Fever, University of California, Bile, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HIV disease progression rates, Administration, Rash, Disease, Ascending cholangitis, Merck & Co., Risk, Immunotherapy, ORR, University, Anemia, RECIST, BTC, Hepatitis, Biliary tract, Lymphocyte, ALT, OS, Death, Toxicity, Hematopoietic stem cell transplantation, CI, Pharmaceutical industry, Vaccine, Merck

Median OS was 12.7 months (95% CI, 11.5-13.6) for KEYTRUDA plus chemotherapy versus 10.9 months (95% CI, 9.9-11.6) for chemotherapy alone.

Key Points: 
  • Median OS was 12.7 months (95% CI, 11.5-13.6) for KEYTRUDA plus chemotherapy versus 10.9 months (95% CI, 9.9-11.6) for chemotherapy alone.
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • For gemcitabine, treatment could be continued beyond eight cycles, while for cisplatin, treatment could be administered for a maximum of eight cycles.
  • There was a difference of ≥5% incidence in laboratory abnormalities between patients who received KEYTRUDA plus chemotherapy versus placebo plus chemotherapy for decreased lymphocytes (69% vs. 61%).

Jona, a Personalized Health Company Using AI to Analyze the Gut Microbiome, Launches with $5M in Funding

Retrieved on: 
Mercredi, novembre 1, 2023
GI, Conditional sentence, Science, FDA, Colitis, Intelligence, LLM, Jim Breyer, Crohn's disease, Health, Food, Assistant, Obesity, Pathology, Motivation, Disease, Doctor of Philosophy, NYU Langone Health, Research, Cardiology, Radiology, Medicine, Autoimmune disease, Diet, DSM-IV codes, NIH, AI, Patient, Diagnosis, Parkinson's disease, Longevity, Antibiotics, Medical device, Pharmaceutical industry, LinkedIn

With its innovative use of LLMs and some of the most advanced applications of generative AI we've seen, the company will change how we think about the microbiome and the future of human health."

Key Points: 
  • With its innovative use of LLMs and some of the most advanced applications of generative AI we've seen, the company will change how we think about the microbiome and the future of human health."
  • Jona's platform aims to equip these individuals with the latest scientific knowledge to discover root causes and develop effective treatment plans.
  • "Launching this company is a culmination of my lived experiences and a lifelong career in artificial intelligence and healthcare."
  • The first product is an easy at-home microbiome profiling kit that sequences the microbes in an individual's gut microbiome.

The Inner Circle Acknowledges, David Chua, M.D., FASGE as a Distinguished Healthcare Professional for his contributions to the Medical Field

Retrieved on: 
Lundi, octobre 30, 2023
House at 200 West North Avenue, Colitis, American College, Mouth, Endoscopy, Gastrointestinal tract, University of Santo Tomas Faculty of Medicine and Surgery, ACG, Rush University, Pancreas, American Board of Commissioners for Foreign Missions, Wayne State University, Liver, American College of Gastroenterology, Society, Non-alcoholic fatty liver disease, Lincoln Park, Medical degree, Colonoscopy, Human, Inner circle, NASH, Wayne, Medical specialty, American Society for Gastrointestinal Endoscopy, IBS, Internal, University, Love, Peptic ulcer disease, Gastrointestinal Endoscopy, Hepatitis, Therapeutic endoscopy, Patient, Parent, Pharmaceutical industry, Gastroenterology, Crohn's disease, Medicine

OAKBROOK, Ill., Oct. 30, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, David Chua, M.D., FASGE is acknowledged as a Distinguished Healthcare Professional for his contributions to the Medical Field.

Key Points: 
  • OAKBROOK, Ill., Oct. 30, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, David Chua, M.D., FASGE is acknowledged as a Distinguished Healthcare Professional for his contributions to the Medical Field.
  • Dr. Chua pursued a Medical Degree from the University of Santo Tomas Faculty of Medicine and Surgery.
  • He is considered an expert in colonoscopy, liver, hepatitis, Crohns, and IBS and Therapeutic Endoscopy.
  • Board certified by the American Board of Internal Medicine-Internal Medicine, and Gastroenterology by the American Board of Internal Medicine- Internal Medicine and Gastroenterology.

Iterative Health Presents Award-Winning Research on the Benefits of Gastroenterological Technology at the American College of Gastroenterology Annual Scientific Meeting

Retrieved on: 
Lundi, octobre 23, 2023
Technology, Surgery, Medical Devices, Medical Supplies, Clinical Trials, Other Health, Health, General Health, Artificial Intelligence, GI, FDA, Intelligence, American College, Harvard Medical School, Crohn's disease, MPH, Outline of health sciences, Adenoma, Use, ACG, Prevalence, Rutgers University–New Brunswick, Cade, Publication, Doctor of Philosophy, MBA, American College of Gastroenterology, Research, Computer science, Computer-aided, George Washington University School of Medicine & Health Sciences, Artificial intelligence, APC, Colonoscopy, School, University of North Dakota, CRC, Clinical trial, Abstract, University, Medical diagnosis, Mount Auburn Hospital, Safety, Boston Medical Center, Inflammatory bowel disease, MS, Medical imaging, Management, Medical device, Gastroenterology, MD, Colitis, Geriatrics, Medicine

Iterative Health , a pioneer in precision-medicine technologies for gastroenterology, announced today the results of new research unveiled at the American College of Gastroenterology (ACG) Annual Scientific Meeting.

Key Points: 
  • Iterative Health , a pioneer in precision-medicine technologies for gastroenterology, announced today the results of new research unveiled at the American College of Gastroenterology (ACG) Annual Scientific Meeting.
  • This research represents strides toward enhancing the detection of precursor adenomas and streamlining clinical trial recruitment processes in gastroenterology, ultimately bringing us closer to a future of advancing patient care in the field.
  • The publications include:
    Authors: William Holderman, MD; Parth Jain; Mitchell Reddan, MS; Haig Soghigian, MBA; Christopher Fourment, MD.
  • To learn more about Iterative Health, please visit iterative.health .

GREENSHIELD ADMINISTRATION RELEASES 2023 DRUG TRENDS REPORT: THE INTRODUCTION OF NEW THERAPIES INCREASE UTILIZATION RATES

Retrieved on: 
Jeudi, octobre 19, 2023
Patient, Lisdexamfetamine, Colitis, Psoriasis, Galcanezumab, Health, Therapy, Social skills, Prevalence, Elijah Cummings Lower Drug Costs Now Act, Migraine, Methylphenidate, Rheumatoid arthritis, RA, Fremanezumab, Crohn's disease, Growth, Disease, Asthma, Pharmacy, Diabetes, Eye, Case management, Calcitonin gene-related peptide, COPD, ADHD, Appetite, Mental health, Pharmaceutical industry, Dietary supplement, Health insurance, Iain Greenshields, Semaglutide

Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.

Key Points: 
  • Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.
  • "In the ever-changing world of healthcare, GreenShield's 2023 Administration Drug Trends Report reveals a compelling narrative, with an overall rise in utilization rates - driven by new therapies and changes in how plan members approach their health," said Mark Rolnick, Executive Vice President, Head of GreenShield Administration.
  • This year's report provides data based on +32 million claims from over two million drug claimants processed by GreenShield Administration this year.
  • Beyond its annual Drug Trends report, GreenShield Administration unlocks better health for all through integrated health and benefits solutions for more than 6 million Canadians from coast-to-coast.

GREENSHIELD ADMINISTRATION RELEASES 2023 DRUG TRENDS REPORT: THE INTRODUCTION OF NEW THERAPIES INCREASE UTILIZATION RATES

Retrieved on: 
Jeudi, octobre 19, 2023
Patient, Lisdexamfetamine, Colitis, Psoriasis, Health, Therapy, Social skills, Prevalence, Elijah Cummings Lower Drug Costs Now Act, Migraine, Methylphenidate, Rheumatoid arthritis, RA, Crohn's disease, Growth, Disease, Asthma, Pharmacy, Diabetes, Eye, Case management, Calcitonin gene-related peptide, COPD, ADHD, Appetite, Mental health, Pharmaceutical industry, Dietary supplement, Health insurance, Iain Greenshields, Semaglutide

Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.

Key Points: 
  • Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.
  • "In the ever-changing world of healthcare, GreenShield's 2023 Administration Drug Trends Report reveals a compelling narrative, with an overall rise in utilization rates - driven by new therapies and changes in how plan members approach their health," said Mark Rolnick, Executive Vice President, Head of GreenShield Administration.
  • This year's report provides data based on +32 million claims from over two million drug claimants processed by GreenShield Administration this year.
  • Beyond its annual Drug Trends report, GreenShield Administration unlocks better health for all through integrated health and benefits solutions for more than 6 million Canadians from coast-to-coast.